Halozyme Therapeutics rose 88.5% in a year. Moderna rose 9.3-fold.

Same industry

HALO against four biotech peers, a year at 100

HALO is up 88.5% in a year. Moderna is up 9.3 times. Of these four, Biogen (+60.1%), Amgen (+44.1%) and Gilead Sciences (+40.9%) did less. Weekly closes, Nov 7, 2025 = 100, on a log scale so a 9.3-fold rise and a 40.9% rise both read honestly.

Share this chart

HALO +88.5%. Moderna ×9.3, Biogen +60.1%, Amgen +44.1%, Gilead Sciences +40.9%. Weekly closes, Nov 7, 2025 = 100, log scale.

Share this chart

End-of-day closes (Databento EOD), the last close of each week. The four peers are the largest US-listed companies by market value in HALO’s SEC industry (Biological Products, (No Diagnostic Substances)) with a year of closes. It shows what the closes did; a move here is not a cause, a forecast or a call.

HALO: stories, the record and filings →